SAN DIEGO--(BUSINESS WIRE)-- Innovus Pharma (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has received approval from Health Canada to market its best-selling, clinically proven Vesele® product as a Natural Health Product (“NHP”) to help improve nitric oxide production involved in symptoms of sexual dysfunction. Vesele® will be available over-the-counter (“OTC”) in 120 capsule bottles in Canada and will not require a prescription. The product will not be reimbursed by the Canadian government, therefore, the Company will be able to set the retail price as it does in the United States. The Company expects to directly launch the product itself through its Beyond Human® sales and marketing platform currently being set up in Canada and through other sales channels.

“We are very excited about having our best-selling product, Vesele® approved by Health Canada,” said Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “We expect to launch Vesele® as well as UriVarx™ either directly to customers and through our Beyond Human® sales and marketing platform in Canada or through a dedicated partner and we look to boosting the sales of these and other products in that country,” continued Dr. Damaj.

In addition to the Company’s proprietary products Vesele® and UriVarx™, Innovus Pharma is selling Zestra®, Zestra Glide® and EjectDelay® sold under the name Uxor™ through its partner Orimed Pharma. The Company has also filed for approval for its product AllerVarx™, and is expected to file for at least two additional product approvals in that country before the end of the year.

About Vesele

Vesele® is a proprietary clinically tested oral formulation of L-Arginine and L-Citrulline with the natural absorption enhancer Bioperine® in patients suffering from sexual dysfunction. Vesele® was formulated to increase blood flow and nitric oxide production.

As previously reported, a U.S. human clinical use survey was completed on Vesele® to evaluate erectile dysfunction and sexual satisfaction in men using Vesele® twice daily for up to four months with the following favorable results:

1. 49.5% increase in erection hardness
2. 44.5% increase in erection maintenance
3. 34.6% increase in desire for sexual activity
4. 34.1% increase the ability to satisfy the partner

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the Vesele® product in Canada if approved in that country, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171018005158/en/